Unknown

Dataset Information

0

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.


ABSTRACT: PURPOSE:The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model. METHODS:Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ?10 mm and lymph nodes of ?15 mm at CT were analyzed. For lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax) were measured. RESULTS:A total of 449 lesions were detected by ?1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87-94) versus 56% (95%CI: 50-62, p?=?0.001), respectively, and more than CT and [18F]FDG-PET/CT combined (84% (95%CI:79-88, p?

SUBMITTER: Verhoeff SR 

PROVIDER: S-EPMC6647180 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Purpose</h4>The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [<sup>89</sup>Zr]Zr-DFO-girentuximab-PET/CT and [<sup>18</sup>F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk  ...[more]

Similar Datasets

| S-EPMC10409919 | biostudies-literature
| S-EPMC5807532 | biostudies-literature
| S-EPMC8578071 | biostudies-literature
| S-EPMC6647232 | biostudies-literature
| S-EPMC8036225 | biostudies-literature
| S-EPMC8176438 | biostudies-literature
| S-EPMC10750192 | biostudies-literature
| S-EPMC7383074 | biostudies-literature
| S-EPMC9324044 | biostudies-literature
| S-EPMC5215071 | biostudies-literature